John Pender
Pulmonary Disease · Fort Worth, TXNPI 1134113913
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,589 and has fallen 98.9% since, to $18 in 2024. That places this record below the midpoint for pulmonary disease clinicians in TX, where the typical reported total is $1,976.
Across 141 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Advanced Respiratory, Inc$377
- GSK$326
- AstraZeneca$324
- Insmed, Inc.$178
- Intuitive Surgical$146
- Boehringer Ingelheim$121
- plus $908 from 22 others
What the payments were for
- Food & beverage$2,380100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Advanced Respiratory, Inc | 27 | $377 |
| GSK | 18 | $326 |
| AstraZeneca | 22 | $324 |
| Insmed, Inc. | 4 | $178 |
| Intuitive Surgical | 2 | $146 |
| Boehringer Ingelheim | 7 | $121 |
| Sunovion Pharmaceuticals Inc. | 16 | $100 |
| AbbVie(2 entities) | 4 | $82 |
| Novartis | 4 | $72 |
| Merck | 4 | $56 |
| Mylan Specialty L.p. | 4 | $55 |
| Gilead | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Pfizer | 3 | $51 |
| La Jolla Pharmaceutical Company | 2 | $49 |
| Genentech USA, Inc. | 2 | $47 |
| Shire North American Group Inc | 3 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Johnson & Johnson | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Paratek Pharmaceuticals, Inc. | 2 | $28 |
| Shionogi Inc | 1 | $23 |
| Vertex | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| United Therapeutics Corporation | 1 | $18 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| Circassia Inc. | 1 | $12 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$118
How this compares
$2,380 in reported general payments places this provider in the 50th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Fort Worth
- Steven KimFort Worth$160K
- Andrew MillerFort Worth$112K
- David OstranskyFort Worth$107K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.